The Combating Counterfeit Pharmaceuticals Act of 2025 expands the existing Fentanyl Sanctions Act to target a broader range of illegal drugs beyond just opioids, including counterfeit pharmaceuticals and counterfeit drug ingredients. The bill defines new terms like "copy-cat ingredients"—substances designed to mimic approved prescription drugs but made through different processes or with lower purity standards—and treats these as violations subject to sanctions. The legislation affects foreign drug traffickers, intelligence agencies, and international partners engaged in combating illicit drug trafficking, while also allowing sanctions to be waived for prescription medications on the federal drug shortage list maintained by the Department of Health and Human Services. The bill gives the Director of National Intelligence authority to delegate responsibilities to subordinates and streamlines intelligence-gathering requirements. No specific funding amounts or implementation timelines are specified in the legislation; rather, it modifies existing law to broaden the scope of prohibited activities and enforcement mechanisms already established under the Fentanyl Sanctions Act.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.